<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017584</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00109119</org_study_id>
    <nct_id>NCT05017584</nct_id>
  </id_info>
  <brief_title>ED90 of 0.75% Bupivacaine for Bilateral Tubal Ligation (BTL)</brief_title>
  <official_title>Determining the ED90 for Intrathecal 0.75% Hyperbaric Bupivacaine for Bilateral Tubal Ligation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the dose of bupivacaine that provides effective&#xD;
      pain management in 90% (ED90) of patients undergoing bilateral tubal ligation. This will&#xD;
      guide anesthesiologists on the most effective dose to minimize intraoperative pain during&#xD;
      this procedure. The goal is to make women as comfortable as possible when they undergo this&#xD;
      procedure while also minimizing the amount of time they are required to remain in the&#xD;
      hospital afterwards for monitoring.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose (in mg) of intrathecal 0.75% hyperbaric bupivacaine that provides effective analgesia in 90% of patients undergoing bilateral tubal ligation as measured by patient reported effectiveness.</measure>
    <time_frame>End of study, up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numerical Pain Rating Scale (NPRS) during surgery</measure>
    <time_frame>End of study, up to 2 years</time_frame>
    <description>Pain rating 0-10 as outlined by the NPRS by patient during procedure, in the post-anesthesia care unit, and overall at discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>End of study, up to 2 years</time_frame>
    <description>Incidence of side effects intra-operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>End of study, up to 2 years</time_frame>
    <description>Presence of absence of nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting</measure>
    <time_frame>End of study, up to 2 years</time_frame>
    <description>Presence of absence of vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itching</measure>
    <time_frame>End of study, up to 2 years</time_frame>
    <description>Presence of absence of itching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor use</measure>
    <time_frame>End of study, up to 2 years</time_frame>
    <description>Number of participants requiring the of vasopressors (phenylephrine and ephedrine). Indicated for blood pressure drops greater than 15% below baseline or &lt; 100mm Hg systolic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>End of study, up to 2 years</time_frame>
    <description>Overall patient satisfaction at discharge as measured by patient report. This will be obtained using a scale of 1-5 where 1 = very unsatisfied, 2 = unsatisfied, 3 = neither unsatisfied or satisfied, 4 = satisfied, and 5 = very satisfied</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Hyperbaric bupivacaine 10.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperbaric bupivacaine 12mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperbaric bupivacaine 13.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperbaric bupivacaine 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric bupivacaine</intervention_name>
    <description>The dose for the first subject (A#X) will be 12 mg 0.75% hyperbaric bupivacaine. Two possible outcomes will be recorded: satisfactory or unsatisfactory anesthesia which is determined by occurrence of intraoperative pain and the need for intraoperative analgesia supplementation. Satisfactory analgesia will be defined as a sensory block to the T8 dermatome and the patient shall require no further supplementation for discomfort during her procedure. Unsatisfactory analgesia will be defined as a block not achieving a T8 dermatomal level or when a patient requests additional medication for discomfort at any time during her procedure.&#xD;
The dose for the next (A#X+1) will be adjusted based on the outcome from previous subjects respectively using up-down sequential allocation method with a biased-coin design. This process will continue in similar fashion with dose adjustments for next subjects to be based on outcome from subjects immediately prior.</description>
    <arm_group_label>Hyperbaric bupivacaine 10.5mg</arm_group_label>
    <arm_group_label>Hyperbaric bupivacaine 12mg</arm_group_label>
    <arm_group_label>Hyperbaric bupivacaine 13.5mg</arm_group_label>
    <arm_group_label>Hyperbaric bupivacaine 15mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  American Society of Anesthesiology class II or III&#xD;
&#xD;
          -  bilateral tubal ligation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient refusal&#xD;
&#xD;
          -  BMI ≥ 50 kg/m2&#xD;
&#xD;
          -  American Society of Anesthesiology class IV or above&#xD;
&#xD;
          -  contraindication to neuraxial anesthesia&#xD;
&#xD;
          -  allergy to bupivacaine&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cameron Taylor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cameron Taylor, MD</last_name>
    <phone>919-668-2024</phone>
    <email>cameron.r.taylor@duke.edu</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tubal ligation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

